Integrated Data with Analytic Expertise for a Competitive Edge in the Breast Cancer Market
A leading pharmaceutical company leveraged NorstellaLinQ’s integrated real-world data and analytic expertise to better understand competitive market shifts, uncover new patient opportunities, and inform strategic decisions that supported sustained commercial success. The company: Identified biomarker-eligible patients with integrated real-world data Learned about disease progression and HCP prescribing behavior Optimized commercialization with data-driven market insights
The Next Wave in Oncology: 7 Innovations Redefining Cancer Treatment in 2024 and Beyond
Oncology is undergoing a transformative shift, with new therapies and technologies driving significant improvements in cancer care. The Next Wave in Oncology explores seven groundbreaking advancements, from antibody-drug conjugates (ADCs) to artificial intelligence, that are redefining how cancer is treated. Staying up to date on these innovations is essential for those navigating the rapidly changing […]
The ADC Market: Hot – or Too Hot to Handle?
Antibody-drug conjugates (ADCs) are a unique class of drug compound, comprising a monoclonal antibody (mAb), a linker, and a cytotoxic payload. Together, these make it possible to target tumors with far greater specificity than with traditional forms of treatment. “This unique design enables ADCs to achieve ‘targeted chemotherapy’ and provides advantages over conventional chemotherapy and […]
What Private Equity’s Growing Investment in Urology Practices Means for Oncology Manufacturers
Over the past five years, private equity groups have slowly increased their acquisition of urology practices, increasing their footprint and influence in the urology channel. While many debate the impact of private equity on healthcare delivery and quality, the PE footprint across U.S. healthcare is expected to grow consistently over the next few years. Private […]
Urology Practices’ Growing Role in Oncology: Three Trends to Watch
In 2024, urology practices continue to expand their role in the oncology treatment space, and proactive pharma companies are increasingly focusing on this channel. Historically, urology practices directed their patients to specialized oncology practices and academic care centers for treatment of advanced genitourinary (GU) cancers, such as prostate cancer or urothelial carcinoma. However, in recent […]
10 Questions That Oncology Manufacturers Should Be Asking About the Stark Law
Even though we knew it was coming, the end of the COVID public health emergency (PHE) on May 11, 2023, still took the healthcare industry by surprise. While the end of the PHE resulted in the rollback of many COVID-19 programs, it also changed the ways that Medicare patients can access oral therapies from community […]
